Laden…
3-[(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol
O-Desmethyltramadol is a substance from the class of phenylpropylamines. Further information will follow after enrichment.
Class
Opioide
Pharmacological context
Mechanism
O-Desmethyltramadol wirkt hauptsächlich als Agonist am...
Short read on known pharmacology
Interactions
4 documented
Curated visible combinations
Risk theme
4 high-risk interactions
Condensed from structured notes
Receptor Targets
Mechanism of Action
Designations
IUPAC: 3-[(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxy-cyclohexyl]phenol
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der Serotonintransporter (SERT/5-HTT) ist ein Natrium-abhängiger Monoamintransporter, der Serotonin aus dem synaptischen Spalt zurück in die präsynaptische Zelle transportiert. Er ist das primäre Ziel von SSRI und MDMA.
Der Noradrenalintransporter (NET) ist ein Monoamintransporter, der Noradrenalin aus dem synaptischen Spalt zurücktransportiert. Er wird von verschiedenen Stimulants und Antidepressiva beeinflusst.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class.
Synapedia Evidence
Frequently checked combinations
Effects & Pharmacology is partially translated. Some details are still being expanded.
O-Desmethyltramadol wirkt hauptsächlich als Agonist am μ-Opioid-Rezeptor und hat zusätzlich eine Wirkung auf den α2-Adrenozeptor, was zu schmerzlindernden Effekten führt.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Reported range 100–200 mg
Total duration 4–6 hours
Oral
| Tier | Dosage |
|---|---|
| Light | 50–100 mg |
| Reported | 100–200 mg |
| Strong | 200–400 mg |
Oral
Onset
30–60 minutes
Peak
1–2 hours
Total duration
4–6 hours
After effects
2–4 hours
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Übelkeit, Schwindel und Atemdepression.
Safer Use
Depressant-risk context
This substance belongs to a context where combinations with opioids, benzodiazepines, alcohol, GHB/GBL, or other sedating substances can increase sedation, blackout, aspiration, and breathing-risk patterns. Risk Check can review warning patterns; it is not medical advice and it cannot clear a combination as safe.
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Some entries are pharmacological class warnings. They are useful safety signals, but not substance-specific clinical validation.
Some combinations can be dangerous. Research before combining substances. For breathing problems, unconsciousness, seizures, chest pain, high fever, or severe confusion, contact emergency services.
Dangerous interaction risk
Detailed interaction narrative is still being translated. This row shows the available risk level and data provenance only.
Dangerous interaction risk
Detailed interaction narrative is still being translated. This row shows the available risk level and data provenance only.
Dangerous interaction risk
Detailed interaction narrative is still being translated. This row shows the available risk level and data provenance only.
Dangerous interaction risk
Detailed interaction narrative is still being translated. This row shows the available risk level and data provenance only.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
Effects that O-Desmethyltramadol shares with related substances.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.